Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

PharmacoEconomics

Volumn 26, Issue 4, 2008, Pages 341-358

  Knapp, Martin ^a,b   Windmeijer, Frank ^c   Brown, Jacqueline ^d   Kontodimas, Stathis ^d   Tzivelekis, Spyridon ^d   Haro, Josep Maria ^e   Ratcliffe, Mark ^d   Hong, Jihyung ^b,d   Novick, Diego ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

Amisulpride, therapeutic use; Antipsychotics, therapeutic use; Clozapine, therapeutic use; Cost utility; Olanzapine, therapeutic use; Quetiapine, therapeutic use; Risperidone, therapeutic use; Schizophrenia, treatment

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HYPNOTIC AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; EUROPE; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; IMPOTENCE; LIBIDO DISORDER; MENSTRUATION DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COSTS AND COST ANALYSIS; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 41449109425     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826040-00006     Document Type: Article

References (60)

1. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14-22
2. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107: 222-32
3. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 2004; 161 Suppl. 2: 1-56
4. Expert Consensus Panels. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60: 1-82
5. Lehman AF, Steinwachs DM. Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
6. National Institute of Clinical Excellence (NICE). Technology appraisal: guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE Guidance 2002 [online]. Available from URL: http://www.nhshealthquality.org/nhsqis/controller?p_service-Content. sho&p_applic=CCC&pContentID=962 [Accessed 2005 Aug 1]
7. Black N. What observational studies can offer decision makers. Horm Res 1999; 51 Suppl. 1: 44-9
8. McKee M, Britton A, Black N, et al. Methods in health services research: interpreting the evidence. Choosing between randomised and non-randomised studies. BMJ 1999; 319: 312-5
9. Woods K. Filling the gap: how big is it? In: Rawlins M, Littlejohns P, editors. Delivering quality in the NHS 2004. Oxford: Radical Medical Press, National Institute for Clinical Excellence, 2004: 11-13
10. Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220-31
11. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005
12. Netten A, Curtis L. Unit costs of health and social care 2002. Canterbury: PSSRU University of Canterbury, 2002
13. Netten A, Curtis L. Unit cost of health and social care 2003. Canterbury: PSSRU University of Canterbury, 2003
14. Netten, A, Curtis L. Unit costs of health and social care 2004. Canterbury: PSSRU University of Canterbury, 2004
15. Monthly Index of Medical Specialities (MIMS). London: Haymarket Publications, 2004 Nov
16. CMP Medica Ltd. Chemist and druggist supplement 2005 [online]. Available from URL: http://www.cddata.co.uk [Accessed 2005 Aug 1]
17. IMS Health Inc., MIDAS®, Q2/2004
18. UK Pharmaceutical Industry Costing Analysis System (PICAS®) [database]. Fort Washington (PA): Data Edge, LLC, 1992 (no longer commercially available)
19. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72
20. Kind P, Hardman G, Macran S. UK population norms for EQ-5D [working paper #172]. York (UK): York Centre for Health Economics, 1999
21. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 17-29
22. Windmeijer F, Kontodimas S, Knapp M, et al. Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: the SOHO study. Int J Technol Assess Health Care 2006; 22: 460-8
23. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-94
24. Santos-Silva JMC, Tenreyro S. The log of gravity. Rev Econ Stat 2006; 88: 641-58
25. Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001: 172-214
26. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52
27. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res 2004; 71: 445-62
28. Woods K. Filling the gap: how big is it? In: Rawlins M, Littlejohns P, editors. Delivering quality in the NHS 2004. Oxford: Radical Medical Press, National Institute for Clinical Excellence, 2004: 11-13
29. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004; 13: 461-75
30. Willke RJ, Glick HA, Polsky D, et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-93
31. Raikou M, Briggs A, Gray A, et al. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Econ 2000; 9: 191-8
32. Szende A. Oppe M, Devlin N, editors. EQ-5D value sets: inventory, comparative review and use guide. Dordrecht: Springer, 2007
33. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080-9
34. Lieberman JA, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med 2005; 353: 1209-23
35. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. Pharmacoeconomics 2000; 17: 383-9
36. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 2004; 165: 18-21
37. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 10: 50-4
38. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics 1999; 15: 469-80
39. Jerrell MJ. Cost-effectiveness of risperidone, olanzapine and conventional antipsychotic medications. Schizophr Bull 2002; 28: 589-605
40. Le Pen C, Lilliu H, Allicar MP, et al. An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France. Encephale 1999; 25: 281-6
41. Palmer CS, Revicki DA, Genduso LA, et al. A cost-effective clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345-55
42. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 693-702
43. Sacristan JA, Gomez JC, Salvador-Carulla L. Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 255-34
44. Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999; 60: 38-45
45. Laux G, Heeg BMS, van Haut BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl. 1: 49-61
46. Gibson P, Damler R, Jackson E, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004; 7: 22-35
47. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62: 749-56
48. Byerly MJ, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003; 54: 742-4
49. Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567-79
50. Fuller MA, Shermock KM, Secic M, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatric Serv 2002; 53: 855-60
51. Hueguelet PH, Girardet F. A Swiss retrospective naturalistic outcome study comparing risperidone and olanzapine in the treatment of schizophrenic inpatients. Schwiezer Archiv fur Neuro und Psychi 2002; 153: 282-8
52. Karki SD, Bellnier TJ, Patil K, et al. Cost effectiveness of atypical antipsychotics in severely and persistently mentally ill patients with schizophrenia and schizoaffective disorders. Drug Ben Trends 2001; 13: 7-12
53. Lecomte P, Hert M, van Dijk Mark M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 2000; 3: 1-11
54. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2005; 21: 683-97
55. Taylor DM, Wright T, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003; 64: 589-97
56. Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004; 7: 569-84
57. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002; 15: 75-81
58. Gureje O, Miles W, Keks N, et al. Olanzapine vs. risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003; 61: 303-14
59. Russo PA, Smith MW, Namjoshi M. Healthcare costs for schizophrenia patients started on olanzapine versus risperidone. Am J Health-Syst Pharm 2005; 62: 610-5
60. Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 2005; 19 (5): 393-410